Key Insights on Gross Profit: Teva Pharmaceutical Industries Limited vs Exelixis, Inc.

Teva vs. Exelixis: A Decade of Gross Profit Trends

__timestampExelixis, Inc.Teva Pharmaceutical Industries Limited
Wednesday, January 1, 20142306800011056000000
Thursday, January 1, 20153327700011356000000
Friday, January 1, 201618490200011859000000
Sunday, January 1, 201743741100010825000000
Monday, January 1, 20188274780008296000000
Tuesday, January 1, 20199346780007536000000
Wednesday, January 1, 20209512660007725000000
Friday, January 1, 202113820970007594000000
Saturday, January 1, 202215531530006973000000
Sunday, January 1, 202317576610007646000000
Monday, January 1, 202421687010008064000000
Loading chart...

Unleashing the power of data

A Tale of Two Pharmaceutical Giants: Teva vs. Exelixis

In the ever-evolving pharmaceutical industry, understanding financial health is crucial. This analysis compares the gross profit trends of Teva Pharmaceutical Industries Limited and Exelixis, Inc. from 2014 to 2023. Teva, a global leader, consistently outperformed Exelixis in gross profit, peaking in 2016 with a staggering $11.9 billion. However, a downward trend followed, with a 41% decline by 2022. In contrast, Exelixis, a rising star, showcased impressive growth, with gross profit surging by over 7,500% from 2014 to 2023, reaching $1.76 billion. This stark contrast highlights Teva's challenges in maintaining its dominance and Exelixis's potential in the competitive landscape. Investors and industry watchers should note these trends as they reflect broader market dynamics and strategic shifts within these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025